[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638849":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":51,"centralContacts":55,"locations":65,"responsibleParty":89,"collaborators":91,"id":98,"slug":38,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":38,"eligibilityCriteria":102,"healthyVolunteers":99,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":38,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":38,"overallStatus":68,"whyStopped":38,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"The Second Affiliated Hospital of Chongqing Medical University","OTHER",[8,15,20,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Nucleotide analogs combined with anti-PD-L1 antibody (ASC22). Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the first 24 weeks Drug: Nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14],"Drug: Anti-PD-L1 antibody (ASC22)","Drug: Nucleotide analogs",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2","Anti-PD-L1 antibody\u002Fpegylated interferon alfa (Peg-IFNα) combined with nucleotide analogs Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the first 24 weeks Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for the second 24 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14,19],"Drug: Peg-IFNα",{"label":21,"type":10,"description":22,"interventionNames":23},"Cohort 3","Peg-IFNα\u002FAnti-PD-L1 antibody combined with nucleotide analogs Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the second 24 weeks Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for the first 24 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14,19],{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort 4","Peg-IFNα combined with nucleotide analogs Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for 48 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[14,19],{"label":29,"type":10,"description":30,"interventionNames":31},"Cohort 5","Nucleotide analogs Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[14],[33,39,47],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Anti-PD-L1 antibody (ASC22)","Once two weeks, 1mg\u002Fkg, subcutaneous injection",[9,16,21],null,{"type":34,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Nucleotide analogs","Once\u002Fday, 1 capsule\u002Ftime, oral",[9,16,21,25,29],[44,45,46],"Entecavir","Tenofovir disoproxil fumarate","Tenofovir alafenamide fumarate",{"type":34,"name":48,"description":49,"armGroupLabels":50,"otherNames":38},"Peg-IFNα","Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection",[16,21,25],[52],{"name":53,"affiliation":5,"role":54},"Hong Ren, MM","STUDY_DIRECTOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":38,"email":60},"Dachuan Cai, MD","CONTACT","+86 18323409779","cqmucdc@cqmu.edu.cn",{"name":62,"role":58,"phone":63,"phoneExt":38,"email":64},"Min Chen, PhD","+86 17338600343","mchen@hospital.cqmu.edu.cn",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"The 2nd affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400010","China",{"type":74,"coordinates":75},"Point",[76,77],106.55771,29.56026,{"lat":77,"lon":76},[80,84,87],{"name":81,"role":58,"phone":82,"phoneExt":38,"email":83},"HONG REN","+8613983888786","renhong0531@vip.sina.com",{"name":85,"role":58,"phone":86,"phoneExt":38,"email":60},"Dachuan Cai","+8618323409779",{"name":81,"role":88,"phone":38,"phoneExt":38,"email":38},"PRINCIPAL_INVESTIGATOR",{"type":90,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[92,94,96],{"name":93,"class":6},"First Affiliated Hospital of Chongqing Medical University",{"name":95,"class":6},"Three Gorges Hospital of Chongqing University",{"name":97,"class":6},"Guizhou Provincial People's Hospital","100638849",false,"NCT07573943","ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection","Inclusion Criteria:\n\n1. Body mass index (BMI) of 18 to 32 kg\u002Fm\\^2;\n2. Serum HBsAg\\\u003C100 IU\u002FmL;\n3. HBV DNA\\\u003C20 IU\u002FmL;\n4. HBeAg-negative.\n\nExclusion Criteria:\n\n1. A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;\n2. Use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;\n3. Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;\n4. Confirmed or suspected decompensated cirrhosis;\n5. Malignant tumors;\n6. Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;\n7. Hepatitis C virus (HCV) antibody (+), HIV antigen\u002Fantibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);\n8. Female in suckling period or pregnancy test (+) during screening;\n9. Subjects who are considered by the researcher to have other factors that are not suitable for the study","ALL","18 Years","70 Years",{"count":107,"type":108},150,"ESTIMATED","INTERVENTIONAL",[111],"PHASE4","Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.",[114],"Chronic Hepatitis b","2026-05-05",{"date":117,"type":118},"2026-05-07","ACTUAL",{"date":120,"type":118},"2024-05-21",{"date":122,"type":108},"2026-12-31",{"name":5,"class":6},1]